

orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by February 11, 1998. Oral presentations from the public will be scheduled between approximately 1 p.m. and 2 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before February 11, 1998, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Closed Committee Deliberations: On February 19, 1998, from 3:45 p.m. to 5:30 p.m., the meeting will be closed to permit discussion and review of trade secret and/or confidential information (5 U.S.C. 552b(c)(4)). The investigational new drug and Phase I and II drug products in process will be presented and recent action on selected new drug applications will be discussed.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: January 27, 1998.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 98-2576 Filed 2-2-98; 8:45 am]

BILLING CODE 4160-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/

496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Pseudomonas Exotoxin A-Like Chimeric Immunogens

David J. Fitzgerald (NCI)

Serial No. 60,052,375 filed 11 Jul 97
(Assignee: United States Government)

Licensing Contact: Robert Benson, 301/496-7056 ext. 267

This invention concerns a recombinantly made chimeric immunogen comprising a non-toxic version of *Pseudomonas* exotoxin A (PE) in which the Ib domain is replaced with a non-native epitope. This immunogen can be used as a vaccine, either as a protein or as DNA, and can elicit humoral, cell-mediated and secretory immune responses against the non-native epitope. The non-native epitope fits into the cysteine-cysteine loop of the Ib domain, thus epitopes normally part of a loop are held in their natural conformation. Chimeric immunogens comprising the V3 loop of the HIV-1 env protein have been shown to raise, in rabbits, neutralizing antibodies against clinical isolates of HIV, some cross-protection was seen. Anti-V3 IgA antibodies were raised upon mucosal administration. The claims cover: (a) Chimeric immunogens, (b) nucleic acids encoding chimeric immunogens, (c) antibodies raised against chimeric immunogens, (d) vaccines and methods of immunization.

Pseudomonas Exotoxin A-Like Chimeric Immunogens for Mucosal Immunity

David J. Fitzgerald (NCI) and Randall J. Msrny (Genentech Corp.)

Serial No. 60/056,924 filed 11 Jul 97
(Assignees: United States Government and Genentech Corporation)

Licensing Contact: Robert Benson, 301/496-7056 ext. 267

This invention claims the use of the chimeric immunogens claimed in 60/052,375 to elicit a secretory IgA-mediated immune response. The inventors have shown that parenteral and mucosal administration of the HIV V3 loop/Exotoxin A chimeric immunogen to rabbits raises both a humoral and cell-mediated immune response against HIV. Both parenteral and mucosal administration result in IgG and IgA antibodies being raised, mucosal administration resulted in higher IgA production. Compositions comprising secretory IgA reactive with the non-native epitope are also claimed.

Pin*Point—A Method To Determine Transcription Factor Binding Site In Vivo

Jay Chung (NHLBI)

Serial Nos. 08/826,622 and 08/825,664
filed 03 Apr 97

Licensing Contact: Joseph Contrera, 301/496-7056 ext. 244

Transcription factors play central roles in many disease processes: cancer, AIDS, developmental aberrations, aging and obesity, just to name a few. Therefore, understanding these disease processes and finding cures for them will be greatly assisted by the capability to determine the genes targeted by the transcription factors in vivo. Toward this end, we have designed an in vivo method (PIN*POINT) Protein Position Identification with Nuclease Tail). In this method, a fusion protein composed of a chosen protein linked to a non-sequence specific nuclease is expressed in vivo and the binding of the protein to DNA is made detectable by the nuclease-induced cleavage near the binding site. For example, p53-nuclease fusion protein expressed in vivo will bind to the p53 binding site and mark it by cleaving the DNA near it. The cleavage site can be identified by a number of techniques currently available. A mammalian expression vector designed to express a fusion protein consisting of a polypeptide of one's choice and the nuclease is available as are expression vectors for Sp1 nuclease, TBP (TATA binding protein)-nuclease (for identifying promoters of genes) and other transcription factors. PIN*POINT is described in a paper soon to be published by Lee et al., (1998) PNAS 95, 060-974.

Dated: January 23, 1998.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 98-2561 Filed 2-2-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Heart, Lung, and Blood Institute Special Emphasis Panel (SEP) meeting:

Name of SEP: Computer Algorithm for the Identification of Unknown Proteins after Peptide Sequencing (Telephone Conference Call).

Date: February 3, 1998.

Time: 3:00 p.m. EST.

Place: Rockledge Building II, Room 7214, 6701 Rockledge Drive, Bethesda, Maryland 20892.

Contact Person: Ivan C. Baines, Ph.D., Two Rockledge Center, Room 7184, 6701 Rockledge Drive, Bethesda, MD 20892-7924, (301) 435-0277.

Purpose/Agenda: To review and evaluate contract proposals.

This meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the application and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than fifteen days prior to this meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

(Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health.)

Dated: January 27, 1998.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 98-2560 Filed 2-2-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Environmental Health Sciences; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute of Environmental Health Sciences Special Emphasis Panel (SEP) meetings:

Name of SEP: SBIR Topic 53: Commercialization of Laboratory Methods for Assessing the Genetics Response to Chemicals, and Topic 55: Methods for Assessing the Estrogenicity and Other Endocrine Activity of Environmental Chemicals. (Telephone Conference Call)

Date: February 23, 1998.

Time: 1:00 p.m.

Place: National Institute of Environmental Health Sciences, East Campus, Building 4401, Conference Room 3446, Research Triangle Park, NC 27709.

Contact Person: Dr. David Brown, National Institute of Environmental Health Sciences,

P.O. Box 12233, Research Triangle Park, NC 27709, (919) 541-4964.

Purpose/Agenda: To review and evaluate contract proposals.

Name of SEP: SBIR Topic 51: Development of Transgenic Teleost Animal Model for Assessing Mutagenesis, and Topic 63: Detection of Mutations in Stem Cell Spermatogonia from Transgenic Mice with Integrated phiX Vector. (Telephone Conference Call)

Date: March 13, 1998.

Time: 1:15 p.m.

Place: National Institute of Environmental Health Sciences, East Campus, Building 4401, Conference Room 3446, Research Triangle Park, NC 27709.

Contact Person: Dr. David Brown, National Institute of Environmental Health Sciences, P.O. Box 12233, Research Triangle Park, NC 27709, (919) 541-4964.

Purpose/Agenda: To review and evaluate contract proposals.

These meetings will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Grant applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Programs Nos. 93.113, Biological Response to Environmental Agents; 93.114, Applied Toxicological Research and testing; 93.115, Biometry and Risk Estimation; 93.894, Resource and Manpower Development, National Institutes of Health)

Dated: January 27, 1998.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 98-2557 Filed 2-2-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Neurological Disorders and Stroke Division of Extramural Activities; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings:

Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel (Telephone Conference Call)

Date: February 19, 1998.

Time: 10:30 a.m.

Place: National Institutes of Health, 7550 Wisconsin Avenue, Room 9C10, Bethesda, MD 20892.

Contact Person: Dr. Katherine Woodbury-Harris, Mr. Phillip Wiethorn, Scientific

Review Administrators, NINDS, National Institutes of Health, 7550 Wisconsin Avenue, Room 9C10, Bethesda, MD 20892 (301) 496-9223.

Purpose/Agenda: To review and evaluate Phase I SBIR Contract Proposal(s).

Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel.

Date: March 19, 1998.

Time: 8:30 a.m.

Place: Holiday Inn, Georgetown, 2101 Wisconsin Avenue, NW, Washington, DC 20007.

Phone: (202) 338-4600.

Contact Person: Dr. Lillian Pubols, Chief, Scientific Review Branch, NINDS, National Institutes of Health, 7550 Wisconsin Avenue, Room 9C10, Bethesda, MD 20892, (301) 496-9223.

Purpose/Agenda: To review and evaluate a grant application.

The meetings will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program No. 93.853, Clinical Research Related to Neurological Disorders; No. 93.854, Biological Basis Research in the Neurosciences)

Dated: January 27, 1998.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 98-2558 Filed 2-2-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Center for Scientific Review Special Emphasis Panel (SEP) meetings:

Purpose/Agenda: To review individual grant applications.

Name of SEP: Behavioral and Neurosciences.

Date: February 11, 1998.

Time: 8:00 a.m.

Place: Radisson Barcelo Hotel, Washington, DC.

Contact Person: Dr. Leonard Jakubczak, Scientific Review Administrator, 6701 Rockledge Drive, Room 5172, Bethesda, Maryland 20892, (301) 435-1247.

Name of SEP: Behavioral and Neurosciences.